Estrella Immunopharma (ESLA) Competitors $1.00 -0.01 (-0.99%) Closing price 05/22/2025 03:58 PM EasternExtended Trading$1.01 +0.01 (+1.00%) As of 05/22/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. KRRO, SLS, FTLF, NKTX, CYBN, TNGX, NLTX, EPRX, ACRS, and ADCTShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Korro Bio (KRRO), SELLAS Life Sciences Group (SLS), FitLife Brands (FTLF), Nkarta (NKTX), Cybin (CYBN), Tango Therapeutics (TNGX), Neoleukin Therapeutics (NLTX), Eupraxia Pharmaceuticals (EPRX), Aclaris Therapeutics (ACRS), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Korro Bio SELLAS Life Sciences Group FitLife Brands Nkarta Cybin Tango Therapeutics Neoleukin Therapeutics Eupraxia Pharmaceuticals Aclaris Therapeutics ADC Therapeutics Korro Bio (NASDAQ:KRRO) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, community ranking, dividends, analyst recommendations, profitability, earnings and valuation. Does the media refer more to KRRO or ESLA? In the previous week, Korro Bio had 7 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for Korro Bio and 0 mentions for Estrella Immunopharma. Korro Bio's average media sentiment score of 0.59 beat Estrella Immunopharma's score of 0.00 indicating that Korro Bio is being referred to more favorably in the media. Company Overall Sentiment Korro Bio Positive Estrella Immunopharma Neutral Which has more volatility and risk, KRRO or ESLA? Korro Bio has a beta of 2.66, suggesting that its stock price is 166% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Do institutionals and insiders hold more shares of KRRO or ESLA? 13.2% of Korro Bio shares are held by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are held by institutional investors. 4.6% of Korro Bio shares are held by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, KRRO or ESLA? Estrella Immunopharma has lower revenue, but higher earnings than Korro Bio. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKorro Bio$4.82M28.85-$81.17M-$9.44-1.57Estrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.85 Do analysts rate KRRO or ESLA? Korro Bio presently has a consensus price target of $102.43, suggesting a potential upside of 591.62%. Estrella Immunopharma has a consensus price target of $16.00, suggesting a potential upside of 1,500.00%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Korro Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor KRRO or ESLA? Korro Bio received 31 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. CompanyUnderperformOutperformKorro BioOutperform Votes32100.00% Underperform VotesNo VotesEstrella ImmunopharmaOutperform Votes1100.00% Underperform VotesNo Votes Is KRRO or ESLA more profitable? Korro Bio's return on equity of -50.25% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Korro BioN/A -50.25% -38.48% Estrella Immunopharma N/A -195.77%-157.28% SummaryKorro Bio beats Estrella Immunopharma on 12 of the 16 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.17M$2.93B$5.33B$8.39BDividend YieldN/A1.64%5.21%4.11%P/E Ratio-3.8531.1826.7119.71Price / SalesN/A398.78386.08120.53Price / CashN/A168.6838.2534.62Price / Book8.333.236.774.50Net Income-$7.31M-$72.35M$3.23B$248.22M7 Day Performance4.28%2.49%0.48%-0.78%1 Month Performance-1.95%2.45%9.10%11.53%1 Year PerformanceN/A-24.98%18.56%8.99% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma1.4842 of 5 stars$1.00-1.0%$16.00+1,500.0%-1.5%$36.17MN/A-3.85N/AKRROKorro Bio2.0182 of 5 stars$15.98+2.7%$112.75+605.6%-70.5%$146.12M$4.82M-1.6970Analyst RevisionGap DownSLSSELLAS Life Sciences Group0.3236 of 5 stars$1.54-1.3%N/A+23.1%$145.60M$1M-2.2310FTLFFitLife Brands4.4166 of 5 stars$15.41-1.9%$20.50+33.0%+0.0%$144.61M$64.47M18.2420Analyst DowngradeNKTXNkarta1.9468 of 5 stars$2.02+4.7%$14.83+634.3%-74.6%$143.34MN/A-1.07140Positive NewsGap UpCYBNCybin2.7033 of 5 stars$6.62-6.1%$86.00+1,199.1%N/A$142.18MN/A-1.5150TNGXTango Therapeutics1.878 of 5 stars$1.31+14.9%$12.33+841.5%-74.8%$141.62M$42.07M-1.1190Positive NewsNLTXNeoleukin TherapeuticsN/A$14.73-1.8%N/A-42.7%$138.43MN/A-4.7490Gap UpHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.1117 of 5 stars$3.86+1.4%$10.50+172.4%+28.3%$138.20MN/A-5.3529ACRSAclaris Therapeutics2.8652 of 5 stars$1.25-0.8%$10.67+753.3%+9.6%$135.35M$18.72M-2.40100Positive NewsADCTADC Therapeutics2.6865 of 5 stars$1.35+5.9%$7.75+476.2%-39.8%$133.39M$70.84M-0.56310 Related Companies and Tools Related Companies Korro Bio Competitors SELLAS Life Sciences Group Competitors FitLife Brands Competitors Nkarta Competitors Cybin Competitors Tango Therapeutics Competitors Neoleukin Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Aclaris Therapeutics Competitors ADC Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ESLA Stock Free ESLA Stock Alerts